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Abstract
The acyl-CoA synthetase 4 (ACSL4) is increased in breast cancer, colon and hepatocellular carcinoma. ACSL4 mainly esterifies
arachidonic acid (AA) into arachidonoyl-CoA, reducing free AA intracellular levels, which is in contradiction with the need for
AA metabolites in tumorigenesis. Therefore, the causal role of ACSL4 is still not established. This study was undertaken to
determine the role of ACSL4 in AA metabolic pathway in breast cancer cells. The first novel finding is that ACSL4 regulates
the expression of cyclooxygenase-2 (COX-2) and the production of prostaglandin in MDA-MB-231 cells. We also found that
ACSL4 is significantly up-regulated in the highly aggressive MDA-MB-231 breast cancer cells. In terms of its overexpression
and inhibition, ACSL4 plays a causal role in the control of the aggressive phenotype. These results were confirmed by the
increase in the aggressive behaviour of MCF-7 cells stably transfected with a Tet-off ACSL4 vector. Concomitantly, another
significant finding was that intramitochondrial AA levels are significantly higher in the aggressive cells. Thus, the
esterification of AA by ACSL4 compartmentalizes the release of AA in mitochondria, a mechanism that serves to drive the
specific lipooxygenase metabolization of the fatty acid. To our knowledge, this is the first report that ACSL4 expression
controls both lipooxygenase and cyclooxygenase metabolism of AA. Thus, this functional interaction represents an
integrated system that regulates the proliferating and metastatic potential of cancer cells. Therefore, the development of
combinatory therapies that profit from the ACSL4, lipooxygenase and COX-2 synergistic action may allow for lower
medication doses and avoidance of side effects.
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Introduction
The acyl-CoA synthetase, ACSL4 or FACL4, belongs to a five-
member family of enzymes that esterify mainly arachidonic acid
(AA) into acyl-CoA [1,2]. A striking feature of ACSL4 is its
abundance in steroidogenic tissues [1]. In contrast, ACSL4 is
poorly expressed in other adult tissues, including breast, liver and
the gastrointestinal tract in general [3,4,5]. Abnormal expression
of ACSL4 in non-steroidogenic tissues has been involved in
tumorigenesis [3,4,6]. In fact, ACSL4 overexpression has been
reported in colon adenocarcinoma, hepatocellular carcinoma and
breast cancer [3,4,5]. In human breast cancer, ACSL4 is
differentially expressed as a function of estrogen receptor alpha
status [5].
The release of AA has been indicated as an important signal
leading to cellular proliferation. AA is, in turn, converted to
different biologically active eicosanoid metabolites by three main
enzymatic activities: lipooxygenase (LOX), cyclooxygenase (COX)
and epooxygenase-cytochrome P450. LOX and COX are known
to play a critical role in cancer progression i.e. growth and
metastasis [7,8,9,10].
Differences in abundance and activity of AA-converting
enzymes may result in variations in the cellular content of
eicosanoids. Therefore, and in view of the potential effects exerted
by AA and derived eicosanoids, the enzymatic release of AA, its
intracellular distribution and concentration are all under rigorous
control within cells. Classically, activation of cytosolic phospholi-
pase A2 has been considered as the rate-limiting step in the
generation of AA. However, an alternative pathway that releases
AA in specific compartments of the cell, e.g. mitochondria, has
been described in steroidogenic tissues [11,12,13,14]. This
pathway, in which the rate-limiting enzyme is ACSL4, provides
arachidonoyl-CoA to a mitochondrial acyl-CoA thioesterase
(ACOT2) that releases AA in mitochondria and directs this fatty
acid to the LOX enzyme for its subsequent conversion to
lipooxygenase metabolites [15,16]. In this pathway, the Translo-
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cator Protein (TSPO) [17], which resides in the outer mitochon-
drial membrane where it associates with the acyl-CoA binding
protein DBI (diazepam binding inhibitor), is a crucial partner in
the regulation of AA levels within the mitochondrion, from where
it is exported for further conversion to eicosanoid products
[16,17].
As for ACSL4, altered TSPO expression has also been involved
in several pathological conditions including breast, colon and liver
cancer [18,19]. Moreover, TSPO expression levels show a strong
correlation with the development of the aggressive phenotype of
different breast cancer cell lines [18,20].
Increased ACSL4 expression, both at mRNA and protein levels
[3], in colon adenocarcinoma cells has been associated with
inhibition of apoptosis and increase in cell proliferation when
compared to adjacent normal tissue. Based on those results, it has
been suggested a role for ACSL4 in reducing free AA levels within
cells and its association with apoptosis [3,6,21]. If this is the case,
the reduction of free AA levels will impair the production of
lipooxygenase and cyclooxygenase metabolites of AA that are
known to potentiate tumor aggressiveness in colon adenocarcino-
ma [3], hepatocellular carcinoma [4] and breast cancer [5]. In
addition, increased expression of cyclooxygenase-2 (COX-2) and
of 5-lipooxygenase (5-LOX) has been reported in aggressive
metastatic breast cancer cells [22,23]. Thus, the role of ACSL4 in
tumorigenesis enhancing the proliferation or invasive potential of
the cells is not clear yet. Therefore, it is important to determine the
role and molecular mechanism that govern the relationship
between ACSL4 expression and the metabolic pathway of AA in
cancer cells. To address this question, we used a breast cancer cell
model to study the relationship between ACLS4 expression and
intramitochondrial AA and its role in the generation of
lipooxygenase and cyclooxygenase metabolites and the develop-
ment of an aggressive cell phenotype.
We found that ACSL4 is significantly up-regulated in highly
aggressive breast cancer cell lines, manifested as higher mRNA
and protein abundance, as compared to less aggressive phenotypes
in breast cancer cells. Functionally, we found that ACSL4 is part
of the mechanism responsible for the increase in breast cancer cell
proliferation, invasion and migration. We also found that the levels
of LOX and COX products of AA are regulated by ACSL4 and
that COX-2 expression is controlled by ACSL4 and lipoxygenated
metabolites. In this mechanism, ACSL4, LOX and COX-2
interact functionally and represent an integrated system that
regulates the proliferation and metastatic potential of cancer cells.
This system seems to act in a concerted manner to promote breast
cancer cell proliferation, invasion and migration.
Results
Expression and functional role of ACSL4 in breast cancer
cell lines
A breast cancer cell model comprising different cell lines with
varying cell proliferation, invasive and metastatic behavior was
used to investigate the possible effect of the differential expression
of ACSL4 on the aggression phenotype. RT-PCR and immuno-
blot analysis (Fig. 1) showed that ACSL4 is expressed in all cell
lines although at different levels, and that increased expression of
the enzyme associates with the reported aggressive phenotype of
each cell line. ACSL4 is usually detected as a duplet in Western
blot experiments [24,25,26]. This is true for both wild type and
transfected ACSL4 as observed in Figures 1 and 2. The gene
encoding ACLS4 shows alternative splicing [24,26] and the
protein is phosphorylated (personal communication), and possibly
acetylated. A member of the long chain acyl-CoA synthetase
family, ACSL1, is acetylated at both the N-terminal and at a lysine
residue and tyrosine residues are found to be phosphorylated [27].
It was also suggested that the different mobility is due to proteolisis
or post-translational modifications such as N-glycosilation [24].
Both alternative splicing and post translational modification
mechanisms can explain the detection of a duplet by Western
blots.
We next analyzed the role of ACSL4 in cell growth, invasion
and migration, in MCF-7 cells overexpressing ACSL4. As
expected, transient transfection of MCF-7 cells with the cDNA
coding for ACSL4 resulted in three-fold protein levels as
determined by Western blot (Fig. 2A). First, we investigated the
effect of ACSL4 overexpression on the proliferation rate of MCF-7
cells. ACSL4 increased the proliferation rate of MCF-7 cells, as
compared to mock-transfected cells (Fig. 2B). ACSL4 overexpres-
sion resulted also in a significant increase in the invasion MCF-7
cells as compared to mock-transfected cells (Fig. 2C).
Overexpression of ACSL4 induced a more rapid cell migration
towards the injury area in a wound healing assay. As observed in
Figure 2D, differences in the wound area between ACSL4-
transfected and mock-transfected cells were evident as early as 4 h
after injury. In addition, ACSL4-overexpression induced a nearly
complete closure of the wound after 12 h, whereas mock-
Figure 1. ACSL4 expression in human breast cancer cell lines. A:
RT-PCR and Western blot analysis for ACSL4 mRNA and protein
expression respectively, were performed as previously described [47].
Using anti-ACSL4 and anti-b-tubulin, specific protein bands were
detected in immunoblots by enhanced chemiluminescence. B: The
integrated optical density of PCR products was quantified and
normalized with the corresponding L19 mRNA bands (closed bars).
The integrated optical density of ACSL4 protein levels was quantified
and normalized with the corresponding b-tubulin signal (open bars).
Data represent the means 6 SD of three independent experiments.
doi:10.1371/journal.pone.0015540.g001
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transfected cells failed to cover the injury area in that time
(Fig. 2D).
We further investigated the role of ACSL4 using small hairpin
RNA (shRNA) to disrupt the expression of endogenous ACSL4 in
the more aggressive cell line MD-MB-231. The shRNA targeting
ACSL4 knocked down the expression of the protein approximately
40% (Fig. 3A), which in turn resulted in inhibition of cell
proliferation (Fig. 3B), invasion (Fig. 3C) and migration (Fig. 3D)
when compared to mock-transfected cells.
Relationship between intramitochondrial AA,
lipooxygenase product levels and aggressiveness of
breast cancer cells
ACSL4 provides arachidonoyl-CoA to the acyl-CoA thioester-
ase, ACOT2, which releases AA in the mitochondrion and directs
this fatty acid to the LOX enzyme for its subsequent conversion to
lipooxygenase metabolites [11,12]. To investigate whether a
similar mechanism operates in breast cancer cells, we studied
ACOT2 expression and intramitochondrial AA and lipooxygenase
metabolites levels in the MDA-MB-231 and MCF-7 cell lines.
ACOT2 expression was also evident in both cell lines (Fig. 4A).
However, significant differences were observed in both mRNA
and protein levels between the non-aggressive and aggressive cell
lines when analyzed by RT-PCR or Western blot (Fig. 4A).
Increased expression of ACOT2 associated with the aggressive cell
phenotype was also observed.
In parallel with the expression of ACSL4 and ACOT2,
intramitochondrial AA levels were significantly higher in MDA-
MB-231 than in MCF-7 cells (Fig. 4B). A similar result was
obtained when the levels of 5-, 12-, and 15-HETE (metabolites of
5-, 12-, and 15-LOX isoforms respectively) were measured
(Fig. 4C). The levels of these three metabolites were significantly
higher in MDA-MB-231 cells as compared to MCF-7 cells, with a
70-fold difference in favor of 5-HETE (Fig. 4C).
Role of ACSL4 and ACOT2 in the production of
lipooxygenase metabolites in breast cancer cells
We then investigated the role of ACSL4 and ACOT2 in the
production of lipooxygenase metabolites by disrupting the
expression of endogenous ACSL4 and ACOT2 in MDA-MB-
231 breast cancer cells. Inhibition of ACSL4 expression by shRNA
decreased the levels of 5-, 12-, and 15-HETE (Fig. 5A) and
resulted in inhibition on cell proliferation (Fig. 5D). The resultant
reduction in cell proliferation was overcome by incubation of the
Figure 2. Effect of ACSL4 overexpression on cell proliferation, migration and invasion in MCF-7 cells. MCF-7 cells were transiently
transfected with the plasmid containing ACSL4 cDNA (pcDNA3-ACSL4) or empty plasmid (mock). A: Forty-eight hours after transfection, ACSL4
protein levels were evaluated by Western blots and immunocytochemistry. The arrows indicate the effect of the transfection in single cells. B:
Seventy-two hours after transfection, cell proliferation was measured by the MTT assay, as previously described [55]. C: Forty-eight hours after
transfection, cellular invasion was measured by the matrigel assay, as previously described [57]. D: Forty-eight hours after transfection, cellular
migration was measured by the wound healing assay, as previously described [56]. D left: contrast micrographs of cells. D right: At the specified time
points, the distance between the wound edges was measured using Image-Pro Plus software. Data represent the means 6 SD of three independent
experiments. ** P,0.01 and *** P,0.001 vs. mock-transfected cells.
doi:10.1371/journal.pone.0015540.g002
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cells with exogenous 5-, 12-, or 15-HETE (Fig. 5D). Changing the
expression level of ACOT2 by sense and antisense treatment of
MCF-7 cells had no effect on cell proliferation (data not shown).
On the other hand, overexpression of ACOT2 in MDA-MB-231
cells increased the levels of lipooxygenase metabolites (Fig. 5B) and
cell proliferation (Fig. 5C) whereas inhibition decreased the
proliferation rate, as compared to mock-transfected cells (Fig. 5C).
In order to confirm the results obtained by transient
transfection, we stably transfected MCF-7 cells with ACSL4 using
the tetracycline (Tet)-off system, as described in Materials and
Methods. As expected, the MCF-7 Tet-off/ACSL4 cell line
showed a significant increase in ACSL4 mRNA and protein, as
compared with MCF-7 Tet-off control cells, and ACSL4
expression was completely repressed by the treatment of the cells
with tetracycline, indicating that the system is fully functional in
this cell line (Fig. 6A).
In this system, further functional studies were performed to
confirm whether an increased ACSL4 expression may lead to
increased cell proliferation and migration as described above.
Indeed, MCF-7 Tet-off/ACSL4 proliferated at a much higher rate
than control cells (Fig. 6E), an effect abrogated by the addition of
tetracycline.
Tetracycline-treated confluent MCF-7 Tet-off/ACSL4 cells
showed a significant delay in cell movement into the injury area
as compared to controls when subjected to the wound healing
assay (Fig. 6D). MCF-7 Tet-off/ACSL4 cells migrated into the
wound area by 12 h, to such an extent that the wound edges were
almost indistinguishable, whereas MCF-7 Tet-off/ACSL4 cells
treated with tetracycline did not.
Intramitochondrial AA content, formation of
lipooxygenase products and expression of COX-2 in MCF-
7 Tet-off/ACSL4 cells
As shown in Fig. 6B, intramitochondrial AA content in MCF-7
Tet-off/ACSL4 cells incubated in the presence of tetracycline was
significantly different from that in those treated in the absence of
tetracycline. The formation of 5-, 12-, and 15-LOX products was
significantly increased in cells overexpressing ACSL4 than in cells
treated with tetracycline (Fig. 6C).
Increased expression of COX-2 associates with an aggressive
phenotype in breast cancer cell lines [28]. We therefore
investigated COX-2 expression levels in the breast cancer cell
model used for ACSL4 expression studies. RT-PCR showed
expression of COX-2 in the different cell lines investigated
(Fig. 7A). Cells with a more invasive potential, such as Hs-578-T
and MDA-MB-231, displayed dramatically increased levels of
COX-2 as compared to the non-aggressive lines MCF-7 and
T47D. Transient transfection of MCF-7 cells with ACSL4 resulted
Figure 3. Effect of ACSL4 knock-down expression on cell proliferation, migration and invasion in MDA-MB-231 cells. MDA-MB-231
cells were transiently transfected with the plasmid containing shRNA-ACSL4 (shRNA-ACSL4) or an empty plasmid (mock). Forty-eight hours post-
transfection, ACSL4 protein levels (A), proliferation (B), invasion (C) and migration (D) were evaluated as described in Fig. 2. Data represent the means
6 SD of three independent experiments. *** P,0.001 vs. mock-transfected.
doi:10.1371/journal.pone.0015540.g003
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in a significant increase in the expression of COX-2, thus
indicating that ACSL4 expression associates with COX-2
expression (data not shown). Accordingly, COX-2 expression is
upregulated in MCF-7 Tet-off/ACSL4 cells whereas tetracycline
treatment of those cells reduced the expression of COX-2 (Fig. 7B).
Figure 4. ACOT2, intramitochondrial AA, and of 5-, 12- and 15-
HETE levels in breast cancer cells. A: Total RNA was extracted from
MCF-7 and MDA-MB-231 cells and subjected to RT-PCR analysis for
ACOT2 mRNA. Mitochondrial proteins were extracted from MCF-7 and
MDA-MB-231 cells and evaluated by Western blot using an anti-ACOT2
antibody [48]. B: Representative autoradiography showing [1-14C] AA
spots from mitochondrial fraction. [1-14C]-AA (New England Nuclear,
Boston, MA, USA; specific activity 53.0 mCi.mmol-1) was added to the
cultures in a concentration of 1 mCi.mmol-1per well (16106 cells) in
serum-free DMEM containing 0.5% fatty acid-free bovine serum
albumin. The mitochondria were isolated, sonicated and lipids were
extracted and analyzed by thin layer chromatography (TLC) on silica gel
plates, as previously described [12]. The autoradiographs were
quantified by densitometry. Bars denote levels (in arbitrary units) of
[1-14C] AA in mitochondria. Results are expressed as the means 6 SD
from three independent experiments. ***P,0.001. C: The levels of 5-,
12- and 15-(S)HETE accumulated for 48 h in the medium were
determined by HPLC [50]. Bars denote levels of the lipooxygenase
metabolites. Results are expressed as the means 6 SD from three
independent experiments. *** P,0.001, ** P,0.01 vs. MCF-7 cells.
doi:10.1371/journal.pone.0015540.g004
Figure 5. Effects of ACSL4 and ACOT2 expression on 5-, 12-
and 15-HETE in MDA-MB-231 cells. A: MDA-MB-231 cells were
transiently transfected with the empty plasmid (mock) or with shRNA-
ACSL4. Forty-eight hours post-transfection, the levels of 5-, 12- and 15-
HETE in the incubation media were analyzed by HPLC. *** P,0.001,
** P,0.01 vs. mock-transfected cells. B: MDA-MB-231 cells were
transiently transfected with the empty pRCMVi plasmid (mock) or
containing ACOT2 cDNA in the sense (ACOT2 sense) orientation.
Seventy-two hours after transfection the lipooxygenase metabolites, 5-,
12- and 15-HETE were analyzed as described. Bars denote levels of the
lipooxygenase metabolites. Results are expressed as the means 6 SD
from three independent experiments. *** P,0.001, ** P,0.01 vs. mock-
transfected cells. C: MDA-MB-231 cells were transiently transfected with
the plasmid containing ACOT2 cDNA in the sense (ACOT2 sense) or
antisense (ACOT2 antisense) orientation Seventy-two hours after
transfection, cell proliferation was measured by the MTT assay. Data
represent the means 6 SD of three independent experiments.
*** P,0.001 and ** P,0.01 vs. mock-transfected. D: MDA-MB-231 cells
were transfected as described in A. Forty-eight hours after transfection,
the cell cultures were incubated with or without 10 mM of 5-, 12- and
15-HETE for 24 h. Cell proliferation was measured by the MTT assay.
Data represent the means6 SD of three independent experiments. a, b,
c P,0.001 vs. shRNA-ACSL4, ** P,0.01 vs. mock-transfected cells.
doi:10.1371/journal.pone.0015540.g005
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To investigate whether the effect on COX-2 expression is
mediated by the lipooxygenase products, we treated the cells with
AA-861, a specific inhibitor of 5-LOX [29]. AA-861 blocked the
effect in COX-2 levels caused by the overexpression of ACSL4 in
the MCF-7 Tet-off/ACSL4 cell line (Fig. 7C). Nordihydro-
guayaretic acid, a more general LOX inhibitor, is also able to
inhibit the effect of ACSL4 on COX-2 expression (data not
shown). Finally, the increase in COX-2 expression in the MCF-7
Tet-off/ACSL4 cell line was accompanied by an increased
production of PGE2 (Fig. 7D).
Discussion
This study was undertaken to clarify the role of ACSL4 in
tumorigenesis. We found that ACSL4 is a key enzyme in the
mechanism of intramitochondrial AA generation and in the
production of lipooxygenase and cyclooxygenase metabolites of
AA in breast cancer cells. Our results, in terms of its overexpression
and inhibition, demonstrate that ACSL4 plays a causal role in the
control of breast cancer aggressiveness. Also, we report here for the
first time, that ACSL4 controls the expression of COX-2 in those
Figure 6. Effect of ACSL4 expression on cell migration and proliferation of MCF-7 Tet-off/ACSL4 cells. MCF-7, MCF-7 Tet-Off and MCF-7
Tet-off/ACSL4 cDNA cells were incubated with or without tetracycline. A: After 48 h of tetracycline treatment, total RNA was extracted and subjected
to RT-PCR analysis for ACSL4 and L19 mRNA expression. Cellular proteins were obtained and subjected to SDS-PAGE and Western blot analysis. B:
MCF-7 Tet-Off/ACSL4 cells were incubated with or without tetracycline. After 48 h, the cells were labeled with [1-14C] AA (1 mCi/ml) as described in
fig. 4 and intramitochondrial [1-14C] AA levels were analyzed by TLC. Bars denote levels (in arbitrary units) of [1-14C] AA in mitochondria. Results are
expressed as the means 6 SD from three independent experiments. *** P,0.001 vs. without tetracycline. C: MCF-7 Tet-Off/ACSL4 cells were
incubated with or without tetracycline. Forty-eight hours after transfection the lipooxygenase metabolites, 5-, 12- and 15-HETE were analyzed as
described. Results are expressed as the means 6 SD from three independent experiments. *** P,0.001, * P,0.05 vs. without tetracycline. D: Cell
migration was measured by the wound healing assay at the indicated time points. Data represent the means 6 SD of three independent
experiments. *** P,0.001, ** P,0.01 vs. without tetracycline. E: Cell proliferation was measured by the MTT assay at the indicated time points. Data
represent the means 6 SD of three independent experiments. *** P,0.001, ** P,0.01 * P,0.05 vs. MCF-7 Tet-Off/ACSL4.
doi:10.1371/journal.pone.0015540.g006
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cells. Our results provide evidence of the involvement of ACSL4 in
the mechanism responsible for the increase in proliferation, invasion
and migration shown in breast cancer cells.
We found that ACSL4 mRNA and protein levels correlate with
the aggressive phenotype in four different breast cancer cell lines.
Consequently, transient transfection of the low aggressive pheno-
type and low-level expression of ACSL4 cell line, MCF-7, with the
full length human ACSL4 cDNA resulted in increased aggressive-
ness of the cells manifested as augmented cell proliferation, invasion
and migration. In line with these results, inhibition of ACSL4
expression in the highly aggressive and high-level expression of
ACSL4 cell line, MDA-MB-231, by transfection of a plasmid
containing ACSL4-shRNA resulted in decreased aggresiveness.
In a previous report [5] the knock down of ACSL4 in MDA-
MB-231 cells did not change the growth rate of the cells. However,
treatment of these cells with Triacsin C does result in a lower
proliferation rate. The difference between the ACSL4 knock down
experiment in this manuscript and the results reported by Monaco
et. al. [5] may be explained by the protocol used. The protocol
employed by Monaco includes a trypsination step after transfec-
tion and before measurement of cell proliferation rate. Trypsin
treatment may change the proliferation rate as already described
[30] [31,32]. Thus, it can be argued that a longer culture time
should be allowed after cell re-plating following transfection in
order to evidence the effect of ACSL4 knock-down in cell
proliferation rate. Moreover, in our experiments, we used shRNA
instead of siRNA. shRNA constructs allow for sustained effects as
compared to siRNAs [30,31].
Our model of ACSL4 knock-down showed a very clear
reduction in mRNA and protein levels that paralleled the
reduction in cell growth. Moreover these results are further
supported in the stable cells line where the inhibition of ACSL4
protein by tetracycline paralleled the inhibition of cell growth. Our
results agree with those of Liang et al showing that ACSL4 is also
associated with cell proliferation and that its knockdown blocks
proliferation in hepatocellular carcinoma cells [33].
The inhibitory effect of Triacsin C on cell proliferation observed
by Monaco et al could be the result of a synergistic effect of the
inhibitor and of the siRNA. Triacsin C inhibits also ACSL1 and
ACSL3 apart from ACSL4. However, no evidence is available
showing that ACSL1 or ACSL3 activity increase cell proliferation.
Moreover, in colon adenocarcinoma where ACSL4 expression is
associated with an increased proliferation rate, ACSL1 expression
was not changed or was even down-regulated [3]. As for ACSL3, it
has been shown that the antiproliferative effect of Vitamin D in
prostate cancer cells is mediated by ACSL3 overexpression, an
effect that is blocked by Triacsin C [34]. Thus, an effect of
Triacsin C on ACSL3 could only be proliferative. Our results
using a shRNA and a Tet-off approach support the notion that
ACSL4 up-regulation results in increased breast cancer cell
proliferation rate. Altogether, the results obtained by Monaco et
al using Triacsin C would also support the role of ACSL4 on cell
proliferation.
The results obtained with these transient transfections were
confirmed with the finding that MCF-7 Tet-off/ACSL4 cell line
exhibited and increase in cell proliferation, invasion and
migration. The finding that tetracycline abolished the difference
in the aggressive phenotype of MCF-7 Tet-off/ACSL4 cells
strongly indicates that the increase in cell proliferation, invasion
and migration were a direct result of the increased ACSL4
expression. The time points for monitoring wound closure started
when the wound was done. The difference observed in closure
time between transiently-transfected (Fig. 2 and 3) and stably-
transfected cells (Fig. 6) is explained by the fact that serum was
present throughout the experiment in transient transfection while
it was removed from the culture 24 h prior to wound infliction for
stable transfectants (24 h serum starvation). Serum was not
removed in transient transfection experiments in order to preserve
cells from another stressor. On the other hand, stably-transformed
Figure 7. The effect of ACSL4 on COX-2 expression and
prostaglandin biosynthesis. A: Total RNA was extracted from
MCF-7, T47D, MDA-MB-231 and HS-578-T cells and subjected to RT-
PCR analysis for COX-2 mRNA expression. B: MCF-7 Tet-off/ACSL4 cells
were incubated with or without tetracycline. After 48 h of treatment,
total RNA was extracted and subjected to RT-PCR analysis for COX-2
and L19 mRNA expression. Data represent the means 6 SD of three
experiments. *** P,0.001 vs. without tetracycline. C: MCF-7 Tet-off/
ACSL4 cells were incubated in the presence or absence of the 5-LOX
inhibitor, AA861 (20 mM). After 48 h of treatment, cellular proteins were
obtained and subjected to SDS-PAGE and Western blot analysis using
anti-COX-2 and anti-b-tubulin antibodies sequentially. Specific bands
were detected by enhanced chemiluminescence. The integrated optical
density of COX-2 protein levels were quantified for each band and
normalized with the corresponding b-tubulin signal. D: MCF-7 Tet-off/
ACSL4 or stably transfected with the empty vector were incubated with
or without tetracycline. PGE2 accumulated for 48 h in the culture
medium was analyzed by HPLC. Results are expressed as the means 6
SD from three independent experiments. ** P,0.001 vs. without
tetracycline.
doi:10.1371/journal.pone.0015540.g007
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cells are not subjected to transfection immediately before the
wound experiment and it is, therefore, preferable to perform the
assay with 24 h serum starvation prior to wound infliction to avoid
cell growth during wound closure. Both approaches are accepted
and used in the literature.
Another significant finding was that intramitochondrial AA
levels were significantly increased in MDA-MB-231 cells as
compared to those in MCF-7 cells and that increased AA levels
correlated with higher expression levels of ACSL4. In addition we
also found a 70-, 5-, and 3-fold increase in the levels of 5-, 15- and
12-HETE respectively in MDA-MB-231 as compared to MCF-7
cells. We have observed, concordant with what it is reported in the
literature [28] a higher 5-LOX expression in MDA-MB-231 when
compared to MCF-7 cells. However, overexpression of ACSL4
resulted in slight by not statistically significant increase in 5-LOX
expression (data not shown). The involvement of ACSL4 in the
regulation of intramitochondrial AA levels and lipooxygenase
products were confirmed by inhibition of ACSL4 expression and
the use of the MCF-7 Tet-off/ACSL4 transfection approach.
We also found that ACOT2 is significantly up-regulated in
highly aggressive breast cancer cells. Interestingly, neither
overexpression nor inhibition of ACOT2 expression in MCF-7,
a cell that expresses low amounts of ACSL4, has an effect on cell
proliferation. However, the phenotype was changed by both
overexpression and knockdown of ACOT2 in MDA-MB-231 cells
that express high levels of ACSL4. In addition overexpression of
ACOT2 also increased the levels of the lipooxygenase metabolites.
These results support the hypothesis that ACSL4 is the rate-
limiting enzyme and that it works in combination with ACOT2 to
generate intramitochondrial AA and the lipooxygenase metabo-
lites as already reported for steroidogenic cells [11,12,13,14].
In agreement with a previous work [28], we also found that
COX-2 is expressed at much higher levels in MDA-MB-231 cells
than in MCF-7 cells. Notably, the high abundance of COX-2
correlates with the higher expression levels of ACSL4. Stable
transfection of MCF-7 cells with the full-length ACSL4 cDNA
under the control of a tetracycline response element resulted in
increased COX-2 constitutive expression. The finding that
tetracycline abolished the expression of COX-2 strongly indicates
that COX-2 expression is under the control of ACSL4 levels. In
this work, we state that COX-2 expression in the more aggressive
cells is controlled by ACSL4 through the generation of
lipooxygenase metabolites since inhibition of lipooxygenase
activity blunted ACSL4-dependent increase in COX-2 expression.
This is an important finding that contributes to the understanding
of the mechanism that controls COX-2 expression in breast cancer
cells. The conclusion that ACSL4 may regulate COX-2 expression
through the activation of lipoxygenase products is in line with
previous observations showing that leukotriene B4, a product of 5-
HETE, positively regulates the levels and stability of COX-2
mRNA and protein expression in synovial living cells [33].
Leukotrienes D4 (LTD4) is also known to stimulate COX-2
expression in intestinal and colon cancer cells [34].
Lipoxygenase inhibition can cause apoptosis. Thus, an apoptotic
effect of AA861, other than its selective inhibition of lipoxygenase
activity and causing a non-specific reduction in cell viability or
survival rate, could be the cause of the attenuation of ACSL4
stimulation of COX-2. In our studies, we used a 20 mM
concentration of AA861 during 48 h of incubation. In another
study using MDA-MB-231 breast cancer cells, a 10 mM concen-
tration of AA861 reduced cell proliferation rate in less than 10%
only after 5 days of culture [22]. In the same study, this modest
inhibition was only observed in two out of five different cell lines
assayed [22]. Other cancer cell lines, such as HT29 human colon
cancer cells, the effect of AA861 on survival and proliferation was
only apparent with concentrations of AA861 above 30 mM [35].
Furthermore, a significant inhibition of cell growth of bladder
cancer cells is reported with 20 mM AA861 again only after 5 days
of culture [36]. It is therefore unlikely that the inhibition of ACSL4-
stimulated COX-2 expression by AA861 reported here may be due
to an activation of apoptosis or inhibition of cell growth or survival
since the inhibition of COX-2 expression is evident at least 48 h
earlier than the inhibition in cell proliferation described for different
cancer cell lines. Also, since COX-2 inhibitors are known to induce
apoptosis [37] a causal relationship between lipoxygenase and
COX-2 inhibition with apoptosis seems plausible.
Previous investigations in colon adenocarcinoma or hepatocellular
cells reported that ACSL4 overexpression or inhibition associated
only with increased or decreased cell proliferation respectively
[3,4,6,21,38]. The authors pointed to reduced free AA levels caused
by ACSL4-mediated esterification results in reduced apoptosis and
increased cell growth. We demonstrate here for the first time that the
generation of prostaglandins is dependent on the presence of ACSL4.
Thus, the esterification of AA by ACSL4 provides a way to
compartmentalize the release of AA in the mitochondrion, a
mechanism that serves to drive the specific biotransformation of the
fatty acid instead of reducing the levels of free AA as previously
suggested [3,6,21]. This, in turn, suggests that ACSL4 regulates the
breast cancer cell phenotype through the production of lipooxygenase
and cyclooxygenase metabolites. This may indicate that the
regulation of proliferation, migration and invasion could be due to
the functional interaction of ACSL4, LOX andCOX2. An schematic
representation of the proposed mechanism is shown in Figure 8.
Several LOX products have been shown to stimulate oncogenes
and to produce mitogenic, antiapoptotic and chemotatic effects. In
recent years the participation of 5-LOX in the regulation of cell
proliferation and apoptosis has emerged [39]. In addition to
normal cells, 5-LOX is expressed by a broad variety of cancer cells
including breast cancer cells [22,40,41,42]. Also, a much higher
level of 12-LOX mRNA has been shown in tumorous cells as
compared to normal cells in human breast cancer sections [43].
COX-2 has been suggested as a necessary component of the
cellular and molecular mechanisms behind breast cancer cell
motility and invasion [44,45]. Consequently, it has been shown
that infiltrating mammary carcinoma and intraductal carcinoma
express significant levels of COX-2 whereas normal breast tissues
do not [46]. COX-2 expression is strongly correlated with
increased tumor microvascularity density and plays an important
role in inhibiting apoptosis, stimulating angiogenesis and promot-
ing tumor cell metastasis and invasion [45]. Since ACSL4 controls
the expression of COX-2 through the induction of lipooxygenase
metabolites of AA, as stated above, the functional interaction of
COX-2 and LOX enzymes could have therapeutic implications. It
has been suggested that COX-2 and 5-LOX may have redundant
functions in cancer pathobiology. Romano and Claria [39] have
raised the question of whether, if co-expressed, these arachidonic-
acid-metabolizing enzymes represent an integrated system that
regulates the proliferation and pro-angiogenic potential of cancer
cells. We here provide evidence for such mechanism, in which
ACSL4, LOX and COX-2 metabolites interact functionally. This
interaction leads to the regulation of cell proliferation, migration
and invasion with ACSL4 as the rate-limiting enzyme for
intramitochondrial AA generation and export, for the conversion
to lipooxygenase metabolites and the induction of COX-2.
Previous reports have demonstrated that the simultaneous
activation of the ACSL4 and COX-2 pathways results in a
synergistic anti-apoptotic effect in colon cancer [21]. Moreover, a
combination of classical non-steroideal anti-inflammatory drugs
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aimed at inhibiting COX-2 and Triacsin C targeting ACSL4 has
shown a synergistic pro-apoptotic effect in the colon cancer cell
line HT29 [21]. In this study, we showed that ACSL4 acts in
combination with ACOT2, LOX and COX-2 to generate an
aggressive phenotype in breast cancer cells. Therefore, this
combined action might lead to the development of therapies that
profit from the ACSL4, LOX and COX-2 synergistic action and
allow for lower medication doses and avoidance of side effects.
It can therefore be argued that ACSL4 overexpression might
contribute to the development of an aggressive phenotype in breast
cancer cells by regulating the production of lipooxygenase and
cyclooxygenase metabolites. This might bring about a common
mechanism, at least in tumors known to express high amounts of
ACSL4, such as breast, colon and hepatocellular carcinoma, where
its high expression is associated with tumorigenesis.
Materials and Methods
Dulbecco’s modified Eagle medium (DMEM) and penicillin-
streptomycin solution trypsin-EDTA, G418 (Geneticin), Opti-
MEM were from GIBCO, Invitrogen Corporation (Grand Island,
NY, USA). Fetal Calf Serum was from PAA laboratories GmbH
(Pasching, Austria). AA861 (2-(12-Hydroxydodeca-5,10-diynyl)-
3,5,6-trimethyl-1,4-benzoquinone), 12(S)-hydroxyeicosatetraenoic
acid (12(S)-HETE); 15(S)-hydroxyeicosatetraenoic acid (15(S)-
HETE), 5-S-hydroperoxy eicosatetraenoic acid (5(S)-HETE), 7-
[3-hydroxy-2-(3-hydroxyoct-1-enyl)- 5-oxo-cyclopentyl] hept-5-
enoic acid (PGE2) were from Biomol (Plymouth Meeting, PA,
USA). Puromycin, tetracycline and 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) were purchased
from Sigma Chemical Co (St. Louis, MO, USA). Polyclonal
rabbit anti-human ACSL4 and anti-human ACOT2 antibodies
were generated in our laboratory [47,48], whereas monoclonal
mouse anti-b-tubulin was from Upstate Group Inc (Temecula,
CA, USA). Polyclonal mouse anti-COX-2 antibody was from
Cayman Chemical (Ann Arbor, MI, USA). Polyclonal rabitt anti-
TOM40 (H-300): SC-11414 was from Santa Cruz Biothecnology,
Inc. Horseradish peroxidase-conjugated goat-anti-rabbit and goat-
anti-mouse secondary antibodies, polyvinylidene fluoride mem-
brane was from Bio-Rad Laboratories (Hercules, CA, USA).
Immun-Blot PVDF Membrane was from Bio-Rad Laboratories
(Hercules, CA, USA). Enhanced chemiluminescence (ECL) was
from GE Healthcare (Buckinghamshire, UK). Lipofectamine 2000
was from Invitrogen (Carlsbad, CA, USA). TriZol reagent was
Molecular Research Center (Cincinnati, OH).
Cell cultures
Human breast cancer cell lines MDA-MB-231, MCF-7, T47D,
HS-578-T, were generously provided by Dr. Vasilios Papadou-
poulus (Research Institute of the McGill University Health Centre,
Montreal, Canada´) and obtained from the Lombardi Compre-
hensive Cancer Center (Georgetown University Medical Center,
Washington D.C. USA). The cell lines were maintained in
DMEM medium supplemented with 10% FBS plus 100 U/ml
penicillin and 10 mg/ml streptomycin (complete DMEM).
RNA extraction and semiquantitative RT-PCR
Total RNA was extracted using TriZol reagent (Molecular
Research Center) following the manufacturer’s instructions.
Figure 8. Schematic model of the signaling pathway involved in ACSL4-induced up-regulation of intramitochondrial AA, LOX
products, COX-2 and PGE2 production in the development of an aggressive phenotype in breast cancer cells. Numbers (1-8) represent
the schematic sequence of events that regulate cell proliferation, migration and invasion. 1, ACSL4 induction and action; 2, Acot2 induction and
action; 3, 5-LOX action; 4, AA metabolism and function; 5, COX-2 induction and action; 6, PGE2 synthesis; 7, PGE2 action; 8, LOX metabolites action.
doi:10.1371/journal.pone.0015540.g008
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Primers used for ACOT2 amplification (amplicon size 870 bp)
were: sense primer, 59-AGATCATTAGGGTTCCTGCTCG-39
and the antisense primer, 59-TTGATGCGATTTCTGTTGA-
CG-39. For ACSL4 amplification (amplicon size 115 bp), the sense
primer, 59-GAAGGTAAAAAGTTAACAGGCAAACAT-39, and
the antisense primer, 59-TCAGAGTTTAAATCTCTTTCCCA-
GGTT-39, were used. Primers used for amplification of the 406-bp
segment of COX-2 were: sense: 59-GCTCAGCCATACAG-
CAAATCC-39, and antisense: 59-GGGAGTCGGGCAATCA-
TAAG-39. The amplified L19 ribosomal protein product of each
sample (amplicon size 500 bp) were used as housekeeping gene
[49]. Specific primers for L19 were: sense: 59-AGTATGCT-
CAGGCTTCAGAA-39, and antisense: 59-TTCCTTGGTCT-
TAGACCTGC-39. The reaction conditions were one cycle of
94uC for 5 min, followed by 37 cycles for ACSL4 or 25 for L19 of
94uC for 30 sec, 60uC for 30 sec, and 72uC for 45 sec, 32 cycles for
ACOT2 of 94uC for 30 sec, 60uC for 30 sec, and 72uC for 1 min.
The number of cycles used for COX-2 was optimized indepen-
dently for MDA-MB-231 (33 cycles) and MCF7 Tet-Off/ACSL4
(35 cycles) followed by 94uC for 30 sec, 60uC for 30 sec, and 72uC
for 45 sec. The number of cycles used was optimized for each gene to
fall within the linear range of PCR amplification. PCRs for ACOT2
amplification included 5% dimethylsulfoxide (DMSO). PCR
products were resolved on 1.5% (wt/vol) agarose gels containing
ethidium bromide. The gel images were digitally recorded and the
amplicons levels were quantitated using the computer-assisted image
analyzer Gel-Pro (IPS, North Reading, MA).
Plasmid transfection
For transient transfection of MDA-MB-231 and MCF-7, cells
were seeded the day before and grown up to 80% confluence.
Transfection was performed with the pcDNA3.1(+) (Invitrogen)
plasmid containing ACSL4 cDNA, the pSUPER.retro plasmid
(OligoEngine) containing shRNA ACSL4 (59 AAGATTATTC-
TGTGGATGA 39) or the empty vectors as control in Opti-MEM
medium and Lipofectamine 2000 reagent (Invitrogen). Transfec-
tion efficiency was estimated at approximately 40% as estimated
by counting fluorescent cells transfected with the pRc/CMVi [11]
plasmid containing the enhanced form of green fluorescent
protein.
Analysis of AA metabolites
12(S)-HETE; 15(S)-HETE, 5(S)-HETE and PGE2 were ana-
lyzed in the culture media of MDA-MB-231, MCF-7 and MCF-7
Tet-Off/ACSL4 cell lines by HPLC as previously described [50].
Briefly, 16106 cells were seeded in tissue culture dishes and
incubated for 48 h in 2 ml of complete DMEM. The AA
metabolites released to the culture media were extracted using
Strata C18-T cartridges (Phenomenex, Torrance, CA, USA),
eluted with 100% methanol. The solvent was evaporated and the
residue was reconstituted in 0.1 ml of solution of methanol/water,
1:2 v/v, and injected into a Hewlett-Packard 1100 HPLC
connected to a UV detector. Quantification of AA metabolites
was obtained by means of standard curves containing the same
synthetic compounds (Biomol Co).
Stable transfection of MCF-7 Tet-off cells with ACSL4
cDNA
The tetracycline-repressible MCF-7 cell line, designated MCF-7
Tet-off, was used for stably transfection of ACSL4 cDNA under
control of the tetracycline-response element using the Tet-Off
Gene Expression System (Clontech). After transfection, cells were
maintained in complete DMEM supplemented with 0.3 mg/ml
puromycin. After several weeks, colonies in which the expressed
ACSL4 was regulated by tetracycline (2 mg/ml) were selected,
cultured and subjected to different functional assays. MCF-7 Tet-
off-induced repression of ACSL4 cells, designated MCF-7 Tet-off/
ACSL4, were further maintained in complete DMEM.
Western blot
Total or mitochondrial proteins (20 mg) were separated on SDS-
PAGE and electro-transferred to poly(vinylidene difluoride)
membranes (Bio-Rad Laboratories) as described previously [11].
Membranes were then incubated with 5% fat-free powdered milk
in 500 mM NaCl, 20 mM Tris-HCl (pH 7.5), and 0.5% Tween
20 for 60 min at room temperature, with gentle shaking. The
membranes were then rinsed twice in 500 mM NaCl, 20 mM
Tris-HCl (pH 7.5), and 0.5% Tween 20 and incubated overnight
with the appropriate dilutions of primary antibody at 4uC: 1:500
rabbit polyclonal anti-ACOT2, 1:1,000 rabbit polyclonal anti-
ACSL4, 1:5,000 mouse monoclonal anti-b-tubulin, and 1:400
rabbit polyclonal anti-Cox-2. Bound antibodies were developed by
incubation with secondary antibody 1:5,000 goat anti-rabbit and
1:5,000 goat anti-mouse horseradish peroxidase conjugated and
detected by chemiluminescence. The inmunoblots were then
quantitated using Gel Pro Analyzer.
Isolation of mitochondria
Isolation of mitochondria was done as described [12]. Briefly,
cell cultures were washed with PBS, scraped in 10 mM Tris-HCl
(pH 7.4), 250 mM sucrose, 0.1 mM EDTA, 10 mM leupeptin,
1 mM pepstatin A, and 1 mM EGTA (buffer A), homogenized
with a Pellet pestle motor homogenizer (Kimble Kontes, Vineland,
NJ), and centrifuged at 6006 g for 15 min. The supernatant
obtained was centrifuged at 10,0006g for 15 min and rendered a
mitochondrial pellet that was washed once with buffer A and
resuspended in 10 mM Tris-HC (pH 7.4), 10 mM leupeptin, 1 mM
pepstatin A, and 1 mM EGTA. Fractions were subjected to
enzymatic analysis to assess their purity (according to [51,52]).
The purity of each fraction was at least 90%, value similar to
previous publications [53].
[1-14C] AA incorporation in breast cancer cells
Cells were labeled according to previously described method-
ology [54], with minor modifications [12]. [1-14C]AA (NEN Life
Science Products, Boston, MA; specific activity 53 mCi/mmol)
was added to the cultures (1 mCi/ml per well; 1 well = 26106 cells)
in serum-free culture media containing 0.5% fatty acid-free BSA.
After 5 h of incubation at 37uC in a humidified atmosphere
containing 5% CO2, cells were washed with serum-free culture
medium containing 0.5% fatty acid-free BSA. A steady state level
is attained between 3 to 4 h, with an uptake of around 85%. The
uptake reaches a plateau and it is sustained for 24 h. This uptake is
similar in MCF-7 and MDA-MB-231 cells and is in accordance
with previous observations in other cells. Mitochondrial pellets
were obtained and resuspended as described above and were then
sonicated. Protein concentration was measured and lipids were
extracted from equal amounts of mitochondrial proteins (500 mg)
from each treatment having previously added 500 ng of unlabeled
AA.
Lipid extraction was performed twice with ethyl acetate (six
volumes per one volume of mitochondrial fraction). The organic
phase was then collected and dried under nitrogen at 25uC and
analyzed by two successive thin-layer chromatographies on silica
gel. Radioactive spots were developed using a Storm phosphor-
imager (Amersham Biosciences, Stockholm, Sweden) after 1 week
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of exposition, and the spot intensities were analyzed using
ImageQuant
Cell proliferation assay
Cell proliferation was measured by the MTT assay, as
previously described [55]. Cells were plated at a density of 4000
cells/well in 96-well plates with 10% FBS-supplemented D-MEM
medium and allowed to adhere overnight at 37uC in a humidified,
5% CO2 atmosphere. The medium was then changed to serum-
free medium. After 24 h, the cells were switched to 10% FBS-
supplemented D-MEM medium and incubated for the appropri-
ate times as described in figure legends. Subsequently, MTT was
added and incubated for 2:30 h at 37uC. Next, the formed
formazan crystals were dissolved with DMSO. The absorbance
570 nm was determined using a Multi-detection microplate
reader, Synergy HT, Biotek (Winooski, Vermont, USA).
Wound-healing assay
Cellular migration was measured by the wound healing assay, as
previously described [56]. Cells (76105 cells per well) were seeded
in six-well plates. Stable-transfectants were serum-starved for 24 h
after which media was replaced (10% FBS medium) and the
wound performed. Transiently-transfected cells were kept in
complete (10% FBS) medium at all times. Wound infliction was
considered as 0 time and wound closure monitored for up to 24 h
wound closure. Cell monolayer was wounding with a plastic tip
across the monolayer cells. Wound closures were photographed by
a phase contrast microscopy (40X) in the time point 4, 6, 12 and
24 h after scraping. The width of the wound was determined with
the program Image Pro-Plus.
Invasion assay
Cellular invasion was measured by the matrigel assay, as
previously described [57], with minor modifications. The in vitro
invasion potential was evaluated using Matrigel-coated invasion
chambers with an 8-mm pore size (BD Biosciences). Briefly, 56104
cells/ml were allowed to migrate for 22 h through the Matrigel-
coated membranes using 5% fetal bovine serum (FBS) as
chemoattractant. Cells that reached the lower surface of the
membrane were stained and counted The number of invaded cells
in six randomly selected microscopic fields per membrane was
counted using an epifluorescence microscope Olimpus BX50 with
a digital camera Cool/Snap Proof Color PM-c35.
Statistics
Statistical analysis was performed by Student’s t test or ANOVA
followed by the Student-Newman-Kuels test.
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